EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY-NC 4.0

Impact of diagnostic and end‐of‐induction Curie scores with tandem high‐dose chemotherapy and autologous transplants for metastatic high‐risk neuroblastoma: A report from the Children's Oncology Group

Keri A Streby iD, Marguerite T Parisi, Barry L Shulkin iD, Brian LaBarre, Rochelle Bagatell, Lisa Diller, Stephan A Grupp, Katherine K Matthay iD, Stephan D Voss iD, Alice L Yu, Wendy B London iD, Julie R Park und 2 weitere

Pediatric Blood & Cancer · 2023

DOI: 10.1002/pbc.30418 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Pediatric Blood & Cancer, 2023. Verfasst von Keri A Streby und 13 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology/Oncology/BMT, Department of Pediatrics, Nationwide Children's Hospital, The Ohio State University, Columbus, Ohio, USA. Hauptthemen laut MEDLINE: Hematopoietic Stem Cell Transplantation, Neuroblastoma. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Diagnostic mIBG (meta‐iodobenzylguanidine) scans are an integral component of response assessment in children with high‐risk neuroblastoma. The role of end‐of‐induction (EOI) Curie scores (CS) was previously described in patients undergoing a single course of high‐dose chemotherapy (HDC) and autologous hematopoietic cell transplant (AHCT) as consolidation therapy.

Objective

We now examine the prognostic significance of CS in patients randomized to tandem HDC and AHCT on the Children's Oncology Group (COG) trial ANBL0532. Study design A retrospective analysis of mIBG scans obtained from patients enrolled in COG ANBL0532 was performed. Evaluable patients had mIBG‐avid, International Neuroblastoma Staging System (INSS) stage 4 disease, did not progress during induction therapy, consented to consolidation randomization, and received either single or tandem HDC ( n = 80). Optimal CS cut points maximized the outcome difference (≤CS vs. >CS cut‐off) according to the Youden index.

Results

For recipients of tandem HDC, the optimal cut point at diagnosis was CS = 12, with superior event‐free survival (EFS) from study enrollment for patients with CS ≤ 12 (3‐year EFS 74.2% ± 7.9%) versus CS > 12 (59.2% ± 7.1%) ( p = .002). At EOI, the optimal cut point was CS = 0, with superior EOI EFS for patients with CS = 0 (72.9% ± 6.4%) versus CS > 0 (46.5% ± 9.1%) ( p = .002).

Conclusion

In the setting of tandem transplantation for children with high‐risk neuroblastoma, CS at diagnosis and EOI may identify a more favorable patient group. Patients treated with tandem HDC who exhibited a CS ≤ 12 at diagnosis or CS = 0 at EOI had superior EFS compared to those with CS above these cut points.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hematopoietic Stem Cell TransplantationNeuroblastomaChildHumansInfant3-IodobenzylguanidineTransplantation, AutologousRetrospective StudiesAntineoplastic Combined Chemotherapy ProtocolsDisease-Free Survival

Stichwörter der Autor:innen

Curie scoremIBGneuroblastomatandem

Substanzen

3-Iodobenzylguanidine

Autor:innen und Institutionen

  • Division of Hematology/Oncology/BMT, Department of Pediatrics, Nationwide Children's Hospital, The Ohio State University, Columbus, Ohio, USA.
  • Department of Radiology, Seattle Children's Hospital, University of Washington School of Medicine, Seattle, Washington, USA.
  • Department of Pediatrics, Seattle Children's Hospital, University of Washington School of Medicine, Seattle, Washington, USA.
  • Department of Radiological Sciences, St. Jude Children's Research Hospital, University of Tennessee Health Science Center, Memphis, Tennessee, USA.
  • Children's Oncology Group Statistics & Data Center, Department of Biostatistics, University of Florida, Gainesville, Florida, USA.
  • Department of Pediatrics, Children's Hospital of Philadelphia and University of Pennsylvania, Philadelphia, Pennsylvania, USA.

ORCID-Profile: Keri A Streby, Barry L Shulkin, Katherine K Matthay, Stephan D Voss, Wendy B London

Förderung

  • NCI NIH HHS

Zitieren

APA

Streby, K. A., Parisi, M. T., Shulkin, B. L., LaBarre, B., Bagatell, R., Diller, L., Grupp, S. A., Matthay, K. K., Voss, S. D., Yu, A. L., London, W. B., Park, J. R., Yanik, G. A., & Naranjo, A. (2023). Impact of diagnostic and end‐of‐induction Curie scores with tandem high‐dose chemotherapy and autologous transplants for metastatic high‐risk neuroblastoma: A report from the Children's Oncology Group. Pediatric Blood & Cancer. https://doi.org/10.1002/pbc.30418

Vancouver

Streby KA, Parisi MT, Shulkin BL, LaBarre B, Bagatell R, Diller L, et al. Impact of diagnostic and end‐of‐induction Curie scores with tandem high‐dose chemotherapy and autologous transplants for metastatic high‐risk neuroblastoma: A report from the Children's Oncology Group. Pediatric Blood & Cancer. 2023. doi:10.1002/pbc.30418

BibTeX
@article{Streby2023,
  author = {Streby, Keri A and Parisi, Marguerite T and Shulkin, Barry L and LaBarre, Brian and Bagatell, Rochelle and Diller, Lisa and Grupp, Stephan A and Matthay, Katherine K and Voss, Stephan D and Yu, Alice L and London, Wendy B and Park, Julie R and Yanik, Gregory A and Naranjo, Arlene},
  title = {Impact of diagnostic and end‐of‐induction Curie scores with tandem high‐dose chemotherapy and autologous transplants for metastatic high‐risk neuroblastoma: A report from the Children's Oncology Group},
  journal = {Pediatric Blood & Cancer},
  year = {2023},
  doi = {10.1002/pbc.30418}
}
Kostenlos starten →